Pieter Van Vlierberghe

Visiting Leuven and lab of @CoolsJn is always inspirational. Learning about the amazing work with @Ammarilys Sofie Demeyer @QThillo @AlexandraBVelo1 and the team

Our Erasmus Virtual Hematology Lectures will continue on September 19 at 16.00 CET (every two weeks) with a fantastic line up. us06web.zoom.us/j/89635130792 ID: 896 3513 0792 We will start with Omar Abdel Wahab from MSKCC. Spread the news 📯📯 @AbdelWahablab @intercept_mds

By unlocking the untapped potential of existing medicines in new areas, the #REMEDI4ALL consortium will contribute, together with renowned international collaborators, to address unmet medical needs. ➡️ Find out more here: remedi4all.org #R4ALL #MedicinesRepurposing

The Anticancer Fund is very enthusiastic about this ambitious initiative in #drugrepurposing, or finding new therapeutic options for existing drugs. We have been a leader in this field to find new #cancer treatments and will now join efforts with 24 organisations! #anticancerfund

My first postdoc paper is now online 🥳 EZH2 cooperates with MYCN in driving T cell lymphoma - as a transcriptional activator, independent of its role as a repressor in the PRC2 complex! 👇doi.org/10.1182/blood.… 👇 @vib_ccb @Onco_KULeuven @VIBLifeSciences @BloodJournal

Help shine a light on #GBMDay by sharing one or more of these quick, impactful stats about glioblastoma and inspire others to take action. Your voice will help highlight the need to ensure better treatments, a better quality of life, and cures for GBM patients and caregivers.

Excited to share our latest publication "RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition", opening perspectives for new therapeutic approaches for high-risk neuroblastoma patients. science.org/doi/10.1126/sc…

Today is Glioblastoma Awareness Day and @KaziaTx has joined @NBTStweets to shine a light on the disease! GBM is the most treatment-resistant and deadliest brain cancer. For more info on #GBMDay and an update on $KZIA's potential #treatment, visit bit.ly/3IQOP7S

Splicing dysregulation in human hematologic malignancies: beyond splicing mutations dlvr.it/STz3Bw #immunology

Read our review on how, other than via coding sequence mutations, splicing aberrations can cause blood cancers. We review how the scientific community targets these mechanisms for new generation of therapeutics.

Tomorrow is #GBMDay. We will not stop until we conquer and cure glioblastoma (#GBM) — once and for all. Take action now: braintumor.org/take-action/gb…

Visiting Antwerp with my great friend and mentor ⁦@adolfo_ferrando⁩ 👍 Thanks so much for taking the time to stop ☺️ it was amazing 🤩

Spread the word: still 2 weeks to apply for an interesting post-doc (bioIT) position in our TOBI team #ERC_COG @ugent_fge @crighent career012.successfactors.eu/career?company…

Excited to share our latest publication "RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition" science.org/doi/10.1126/sc… @crighent

PU.1-dependent enhancer inhibition separates Tet2-deficient #hematopoiesis from malignant transformation, by @aivaliotim et al. bit.ly/3yFU5qn @EinsteinMed

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus: buff.ly/3NZX9Dk @JulesMeijerink @prinsesmaximac #Hematology #Oncology

Recent grant funding successes 🎉 = time for recruiting. Join our team! For those considering postdoctoral training and interested in the biology of aging, please get in touch!

🤩Online today @ScienceAdvances our new study on the role of ASNS in cancer and why it cannot predict response to L-asparaginase thanks to @ChicheJohanna @MGrimaReyes and to @laliguecancer @meta_canproject for their support! science.org/doi/10.1126/sc…

Finally first research paper on #Multiomics on T-ALL biology supported and funded from the #H2020 #Twinning @nextlevelEU project! It's #openaccess so you are invited to read! pubmed.ncbi.nlm.nih.gov/35778917/ @ugent @crighent @researchumcg @uni_ulm

It was a pleasure to share my work "Epigenetic regulator HDAC10 is localized mainly in the cytoplasm and its overexpression affects the apoptosis progression in cutaneous T-cell lymphoma cells" at the 6th Polish Congress of Genetics in Cracow 🧬 @igcpan #genetics